Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 19/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 8/20 | 0.55 |
| ▸ | PSMB11 | A5LHX3 | 7/20 | 0.55 |
| ▸ | PSMD11 | O00231 | 7/20 | 0.55 |
| ▸ | PSMD12 | O00232 | 7/20 | 0.55 |
| ▸ | PSMD14 | O00487 | 7/20 | 0.55 |
| ▸ | PSMA7 | O14818 | 7/20 | 0.55 |
| ▸ | PSMD3 | O43242 | 7/20 | 0.55 |
| ▸ | PSMC3 | P17980 | 7/20 | 0.55 |
| ▸ | PSMA1 | P25786 | 7/20 | 0.55 |
| ▸ | PSMA2 | P25787 | 7/20 | 0.55 |
| ▸ | PSMA3 | P25788 | 7/20 | 0.55 |
| ▸ | PSMA4 | P25789 | 7/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 7/20 | 0.55 |
| ▸ | PSMB9 | P28065 | 7/20 | 0.55 |
| ▸ | PSMA5 | P28066 | 7/20 | 0.55 |
| ▸ | PSMB4 | P28070 | 7/20 | 0.55 |
| ▸ | PSMB6 | P28072 | 7/20 | 0.55 |
| ▸ | PSMC2 | P35998 | 7/20 | 0.55 |
| ▸ | PSMB10 | P40306 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10190229 | 0.89 | PSMB5 (0.58) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL3165069 | 0.87 | PSMB5 (0.58) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL10190238 | 0.86 | PSMB5 (0.67) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL607981 | 0.85 | PSMB5 (0.55) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL8296051 | 0.85 | PSMB5 (0.74) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL8256394 | 0.85 | PSMB5 (0.74) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL12125311 | 0.83 | PSMB5 (0.58) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL10190217 | 0.83 | PSMB5 (0.58) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL15291093 | 0.83 | PSMB5 (0.56) | PSMB5PSMB1PSMB11PSMD11PSMD12 | |
| SCHEMBL10190240 | 0.83 | PSMB5 (0.63) | PSMB5PSMB1PSMB11PSMD11PSMD12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8546608-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576206-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB11 1/4885 |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB11 1/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB11 1/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB11 1/4885 |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885PSMB1 4/4885PSMB11 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.